| Autor: |
Shi-Bin, Yan, Zhong-Guang, Chen, De-Liang, Ma, Xin, Lyu, Yan-Li, Wang, Shi-Bing, Chen, Gui-Tao, Jie |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Zhongguo shi yan xue ye xue za zhi. 25(5) |
| ISSN: |
1009-2137 |
| Popis: |
To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma.Eighty-two cases of non-Hodgkin's lymphoma were divided into 2 groups: gemcitabine+oxaliplation(Gem+Oxa) group (42 cases) and vinorelbine+oxaliplatin(Vin+Oxa) group (40 cases) according to chemotherapy regimens. The clinical efficacy, side effects, progression-free survival situation in 2 groups were compared.There was no significant difference on the clinical effects of 2 groups (P0.05); The therapeutic efficacy for B cell lymphoma was higher than that for T cell lymphoma(P0.05); The therapeutic effects for I-II stages was lower than that for III-IV stages(P0.05); The incidences of platelet decline, nausea and vomit, peripheral nerve symptoms in Gem+Oxa group were lower than those in Vin+Oxa group(P0.05); There was no significant difference in the median progression free survival(P0.05).The efficacy of GEMOX regimen for refractory non-Hodgkin's lymphoma has been confirmed to be good, it has distinct clinical curative effect, it can prolong the progression-free survival time in patients with B cell lymphoma, specially for III-IV stages. It can be used as the preferred method for the treatment of patients with refractory NHL. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
